- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 16/46 - Hybrid immunoglobulins
Patent holdings for IPC class C07K 16/46
Total number of patents in this class: 7936
10-year publication summary
|
507
|
584
|
658
|
650
|
624
|
682
|
685
|
604
|
519
|
353
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 4701 |
255 |
| Hoffmann-La Roche Inc. | 3793 |
183 |
| F. Hoffmann-La Roche AG | 7837 |
176 |
| Chugai Seiyaku Kabushiki Kaisha | 1423 |
149 |
| Amgen Inc. | 4427 |
143 |
| Genentech, Inc. | 4104 |
117 |
| Xencor, Inc. | 413 |
115 |
| Janssen Biotech, Inc. | 1764 |
88 |
| Zymeworks Inc. | 253 |
73 |
| The Regents of the University of California | 20745 |
71 |
| Kymab Limited | 275 |
71 |
| Amgen Research (Munich) GmbH | 260 |
64 |
| Merus N.V. | 191 |
63 |
| Ablynx N.V. | 426 |
59 |
| Sanofi | 4301 |
59 |
| Novartis AG | 10262 |
56 |
| Genmab A/S | 474 |
51 |
| Daiichi Sankyo Company, Limited | 1890 |
48 |
| MacroGenics, Inc. | 230 |
47 |
| National Research Council of Canada | 1551 |
47 |
| Other owners | 6001 |